Following the Belviq recall in February 2020 some of those patients on Belviq developing cancer filed Belviq lawsuits alleging a failure to warn about the risk of cancer associated with Belviq.
We are investigating possible Belviq lawsuits that involve patients on Belviq developing cancer. At the present time, our focus for these Belviq lawsuits is pancreatic cancer, colon cancer, rectal cancer, and lung cancer cases. Let us know if we can help you or a family member by submitting an online Belviq Case Evaluation form, sending me an email, or calling us (800-426-9535).
The Belviq recall was announced after the FDA concluded that the potential risk of cancer associated with Belviq (lorcaserin) outweighs its benefits. The FDA noted there was a numerical imbalance in the number of patients on Belviq developing cancer, then pointed out pancreatic cancer, colorectal cancer, and lung cancer, in particular.
For more information relevant to the Belviq lawsuits being filed against the drug company Eisai for failure to warn following the Belviq recall, we direct you to this February 13, 2020, FDA Drug Safety Communication: “FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market“.
[View article at original source]